Research programme: cancer immuotherapies - Formation Biologics

Drug Profile

Research programme: cancer immuotherapies - Formation Biologics

Alternative Names: AVID-100; AVID-200

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator AvidBiologics
  • Developer Formation Biologics; National Research Council Canada
  • Class Antibodies; Drug conjugates; Immunoconjugates; Immunotherapies
  • Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Head and neck cancer; Solid tumours

Most Recent Events

  • 29 Nov 2016 Preclinical trials in Head and neck cancer in Canada (Parenteral) before November 2016
  • 29 Nov 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 29 Nov 2016 Preclinical development for solid tumours is still ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top